BEAVERTON, Ore., Oct 23 (Bernama-GLOBE NEWSWIRE) — via IBN — DataVault AI, Inc. (“DataVault”) (NASDAQ: DVLT), leading the way in AI data experience, valuation, and monetization, and Wellgistics Health, Inc. (“Wellgistics”) (NASDAQ: WGRX), a leader in next-generation pharmaceutical distribution, digital prescription routing, and AI-powered hub fulfillment, today announced the two companies have entered into a non-binding letter of intent to implement manufacturer-to-patient blockchain-enabled smart contracts (“PharmacyChain™”) into Wellgistics proprietary Technology and Physical infrastructure for the prescription drug industry. The goal of the partnership will be to seek to fully digitize tracking of prescription drugs from script to fulfillment in order to ensure the right drug gets to the right patient at the right time, with the right recommendations for safe and effective use. The companies currently contemplate a revenue-sharing arrangement from fees derived from the use of the PharmacyChain by pharmacies.
“Over the past decade, DataVault AI has built a portfolio of patented technologies that position us at the forefront of data monetization and blockchain innovation across multiple industries,” said Nathaniel Bradley, CEO and Co-founder of DataVault AI. “The $634 billion U.S. prescription drug market is entering a new era of digital transformation, and our PharmacyChain™ platform represents a scalable opportunity to drive measurable value for every stakeholder—from manufacturers and physicians to pharmacies, payers, and patients. By integrating blockchain-enabled smart contracts, we’re creating a more efficient, transparent, and accountable prescription ecosystem that aligns financial incentives with improved patient outcomes.”